Oura acquisition raises conflict-of-interest questions for Eli Lilly

Eli Lilly's acquisition of health tech startup Oura, announced this week, is expected to complicate its relationship with a telehealth company marketing GLP-1s. Experts question potential conflicts of interest arising from Lilly's expanded role in digital health and drug distribution. The deal's implications for market competition and regulatory scrutiny remain uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works